SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP - News) will be presenting at the Piper Jaffray London Health Care Conference on Friday, June 23, 2006 at 10:20 a.m. British Summer Time. Todd Myers, chief financial officer, and Stephen Burley, chief scientific officer, of SGX Pharmaceuticals will provide a corporate overview including information on the Company's lead drug candidate, Troxatyl(TM), currently in a pivotal Phase II/III trial for the treatment of third-line acute myelogenous leukemia, and highlights of the Company's strategic collaboration with Novartis to develop BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia. The conference is being held June 22-23 at the Brewery at Chiswell Street in London, England.
